Parameter | Drug | Distributionb | Additional details |
---|---|---|---|
μ IPL a | DU(4, 16) |  |  |
σ IPL a | DU(2, 8) |  |  |
PMF a | TRI(8, 12, 10) | Â | Â |
k max | ARS/DHA | TRI(0.26, 0.47, 0.37)c | PRR = 105.28; KZ = 38 |
ART | TRI(0.12, 0.33, 0.22)c | PRR = 102.9; KZ = 38 | |
LF | TRI(0.18, 0.54, 0.36)c | PRR = 103; KZ = 22 | |
MQ | TRI(0.11, 0.46, 0.28)c | PRR = 102.25; KZ = 22 | |
PQ | TRI(0.33, 0.65, 0.49)c | PRR = 104.6; KZ = 24 | |
γ | ARS/DHA | lnN(1.31, 0.65) |  |
 | ART | lnN(1.53, 0.31) |  |
 | LF | lnN (0.81, 0.58) |  |
 | MQ | lnN (0.97, 0.54) |  |
 | PQ | lnN (1.35, 0.66) |  |
EC50 (ng/mL) | ARS/DHA | U(1.44, 532.05) | a = (adjusted)(ng/mL)b,d; b = 0.5×Cmax (ng/mL)b,d |
 | ART | U(4.38, 46.20) |  |
 | LF | U(1.75, 2331.60) |  |
 | MQ | U(20.48, 1087.22) |  |
 | PQ | U(11.56, 94.19) |  |